Clinical trial • Phase I|Phase III • Respiratory
ATI-052 for Asthma
Phase I|Phase III trial of ATI-052 for Asthma. 10 participants.
Overview
- Trial Therapeutic Area
- Respiratory
- Trial Disease
- Asthma
- Trial Stage
- Phase I|Phase III
Key dates
- Initial CTIS Submission Date
- 23-01-2026
- First CTIS Authorization Date
- 16-04-2026
Eligibility
Recruits 10 Vulnerable population selected (isVulnerablePopulationSelected: true); no further details on consent, assent, or specific vulnerable group handling are provided in the available documents..
- Vulnerable Population
- Vulnerable population selected (isVulnerablePopulationSelected: true); no further details on consent, assent, or specific vulnerable group handling are provided in the available documents.
Recruitment
- Recruitment Window Months
- 8
- Consent Approach
- Not specified in the available data; no details provided on who provides consent, assent processes for minors, age-specific consent documents, or languages available.
Geography
- Total Number Of Sites
- 2
- Total Number Of Participants
- 10
Germany
- Earliest CTIS Part Ii Submission Date
- 30-03-2026
- Latest Decision Or Authorization Date
- 16-04-2026
- Processing Time Days
- 17
- Number Of Sites
- 2
- Number Of Participants
- 10
Sites
- Site Name
- Velocity Clinical Research Germany GmbH
- Department Name
- Velocity Clinical Research Lübeck
- Contact Person Name
- Nakul Modi
- Contact Person Email
- nmodi@velocityclinical.com
- Site Name
- PAREXEL International GmbH
- Department Name
- Early Phase Clinical Unit Berlin
- Contact Person Name
- Javier Hernandez
- Contact Person Email
- Javier.HernandezBuenAbad@parexel.com
Sponsor
Primary sponsor
- Full Name
- Aclaris Therapeutics Inc.
- Organisation Type
- Pharmaceutical company
- Country Of Registered Address
- United States
Investigational products
- Investigational Product Name
- ATI-052
Related trials
Other published trials that may interest you.